> Products > CAS:28721-07-5

China CAS:28721-07-5 Manufacturer

We not only will try our greatest to offer superb companies to just about every buyer, but also are ready to receive any suggestion offered by our shoppers for CAS:28721-07-5, We are going to do our best to fulfill your specifications and are sincerely searching forward to building mutual valuable organization romantic relationship along with you!
CAS:28721-07-5, Welcome to visit our company and factory, there are various solutions displayed in our showroom that will meet your expectation, meanwhile, if you are convenient to visit our website, our sales staff will try their efforts to deliver you the best service

Hot Products

Eslicarbazepine Acetate
Eslicarbazepine Acetate has In-house specification. DMF approved.
CAS:236395-14-5
Valganciclovir Hydrochloride
Valganciclovir Hydrochloride has USP specification. DMF approved.
CAS:175865-59-5
6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy
6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy is the intermediate of Cyproterone acetate.
CAS:17183-98-1
Mono-acetyl Ganciclovir
Mono-acetyl Ganciclovir Specification: Min 97.0%
CAS:88110-89-8
Cyproterone Acetate Tablets
Cyproterone Acetate Tablets Specifications：50mg*24
Indications：Anti-androgen
Abiraterone
Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.
CAS:154229-19-3

Related Blog
Reviews

2023 See us at DCAT Week, CPHI and API exhibition!
CPhI South East Asia 2025-See you at booth N33
CPhI South East Asia 2025 will be held at MITEC, Kuala Lumpur, Malaysia from 16 Jul to 18 Jul 2025, our booth number is N33.
Visit us at CPHI Frankfurt - Booth 12.1C3!
CPHI Frankfurt 2025 will be held at Messe Frankfurt from October 28 to 30, our booth number is 12.1C3.
Are There Any Side Effects or Risks Associated with Levonorgestrel Capsules
As a leading provider in women's reproductive health, we at Humanwell often receive questions from individuals considering emergency contraception. One of the most frequent and important queries we encounter is about the safety profile of Levonorgestrel Capsules.
Can 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic Acid Become the Preferred Intermediate for Modern Pharmaceutical Research
As pharmaceutical innovation continues to advance, the demand for highly pure steroid intermediates has increased significantly. Among these compounds, 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic acid has attracted considerable attention due to its unique molecular structure, stability, and importance in the synthesis of several biologically active steroid derivatives.
Methylprednisolone Market Trends: Key Developments in Corticosteroid Drug Manufacturing
This article looks at key manufacturing trends surrounding Methylprednisolone, including API quality control, specification management, regulatory support, formulation requirements, and the role of experienced steroid API manufacturers such as Humanwell.

China CAS:28721-07-5 Manufacturer

Related Products

Hot Products

Eslicarbazepine Acetate

CAS:236395-14-5

Valganciclovir Hydrochloride

CAS:175865-59-5

6-chloro-1α-chloromethyl-3,20-dioxo-pregna-4,6-dien-17α-acetoxy

CAS:17183-98-1

Mono-acetyl Ganciclovir

CAS:88110-89-8

Cyproterone Acetate Tablets

Abiraterone

CAS:154229-19-3

2023 See us at DCAT Week, CPHI and API exhibition!

CPhI South East Asia 2025-See you at booth N33

Visit us at CPHI Frankfurt - Booth 12.1C3!

Are There Any Side Effects or Risks Associated with Levonorgestrel Capsules

Can 4-aza-5α-androstan-1-ene-3-oxo-17β-carboxylic Acid Become the Preferred Intermediate for Modern Pharmaceutical Research

Methylprednisolone Market Trends: Key Developments in Corticosteroid Drug Manufacturing

Deirdre 2023-09-24 06:46:03

Agatha 2023-01-19 19:35:26

Antonia 2024-04-15 16:58:03

David 2023-10-01 19:46:57

Esther 2023-01-25 11:13:18

Karen 2022-12-20 14:41:29

Send Inquiry